- Home
- INTS vs HYFM Comparison
INTS vs HYFM Comparison
Compare INTS & HYFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- HYFM
- Stock Information
- Founded
- INTS 2012
- HYFM 1977
- Country
- INTS United States
- HYFM United States
- Employees
- INTS N/A
- HYFM N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- HYFM Industrial Machinery/Components
- Sector
- INTS Health Care
- HYFM Industrials
- Exchange
- INTS Nasdaq
- HYFM Nasdaq
- Market Cap
- INTS 12.2M
- HYFM 13.8M
- IPO Year
- INTS 2023
- HYFM 2020
- Fundamental
- Price
- INTS $0.62
- HYFM $2.47
- Analyst Decision
- INTS Strong Buy
- HYFM
- Analyst Count
- INTS 4
- HYFM 0
- Target Price
- INTS $4.50
- HYFM N/A
- AVG Volume (30 Days)
- INTS 85.6M
- HYFM 31.4K
- Earning Date
- INTS 11-17-2025
- HYFM 11-07-2025
- Dividend Yield
- INTS N/A
- HYFM N/A
- EPS Growth
- INTS N/A
- HYFM N/A
- EPS
- INTS N/A
- HYFM N/A
- Revenue
- INTS N/A
- HYFM $161,102,000.00
- Revenue This Year
- INTS N/A
- HYFM N/A
- Revenue Next Year
- INTS N/A
- HYFM $37.86
- P/E Ratio
- INTS N/A
- HYFM N/A
- Revenue Growth
- INTS N/A
- HYFM N/A
- 52 Week Low
- INTS $0.19
- HYFM $1.50
- 52 Week High
- INTS $3.40
- HYFM $8.55
- Technical
- Relative Strength Index (RSI)
- INTS 57.24
- HYFM 39.60
- Support Level
- INTS $0.23
- HYFM $2.22
- Resistance Level
- INTS $1.74
- HYFM $2.57
- Average True Range (ATR)
- INTS 0.14
- HYFM 0.22
- MACD
- INTS 0.06
- HYFM -0.03
- Stochastic Oscillator
- INTS 25.69
- HYFM 23.64
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.